The exact process of chronic lymphocytic leukemia patients developing resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug, has been understood by a multi-institutional team of researchers. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of new agents to treat drug-resistant disease. Ibrutinib received accelerated ...
via Medindia Health News
More READ
No comments:
Post a Comment